Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 1998

View Archived Issues

Behavioral effects of methylene blue studied in animal models

Safety and efficacy of tazarotene gel demonstrated in psoriasis

Novel antiparkinsonian agent displays improved side effect profile

Celltech: Annual Report 1997

Alferon N Injection for HIV-infected patients makes progress

Aminopterin enters phase II for endometrial cancer

Tripos and Sepracor to collaborate on discovery of HIV protease inhibitors

SSRIs appear safe for use during pregnancy

Animal study indicates efficacy of oral PAF antagonist in allergic rhinitis

Ariflo possesses potent antiinflammatory activity, without GI side effects

T-440: a new antiasthma drug candidate from Tanabe

Mechanism of hypolipidemic effects of monatepil elucidated

PAF antagonist protects against ischemia-reperfusion injury in heart-lung transplantation

Cell adhesion inhibitors from Yoshitomi

Agouron discloses new HIV protease inhibitors

IL-6 suggested to be an endogenous neuroprotective factor

Merck describes newly discovered beta3-adrenoceptor agonists

New mitomycin formulation now under FDA review

First NDA filing for Sonata

Ergo Science establishes Ergoset partnership with J&J units

Strengthened safety labeling for Accutane

Baxter to acquire Somatogen

Xenical scheduled for FDA advisory panel review

Oncologic Drugs Advisory Committee meets next month

Priority review status granted for Avakine

Thyrogen will receive priority review by the FDA; EU application also accepted

Cyclopropane analogues as potent anti-HIV-1 agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...